Comparison between Asston Pharmaceuticals IPO and Studio LSD IPO.
Asston Pharmaceuticals IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Studio LSD IPO is a SME Bookbuilding proposed to list at NSE SME.
| Asston Pharmaceuticals IPO | Studio LSD IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Sobhagya Capital Options Pvt.Ltd. | Corpwis Advisors Pvt.Ltd. |
| Registrar | Maashitla Securities Pvt.Ltd. | Purva Sharegistry (India) Pvt.Ltd. |
| Market Maker | JSK Securities & Services Pvt.Ltd. | Rikhav Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Asston Pharmaceuticals IPO is up to ₹26.17 Cr whereas the issue size of the Studio LSD IPO is up to ₹70.53 Cr. The final issue price of Asston Pharmaceuticals IPO is ₹123.00 per share and of Studio LSD IPO is ₹54.00 per share.
| Asston Pharmaceuticals IPO | Studio LSD IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ₹115.00 per share | ₹51.00 per share |
| Issue Price (Upper) | ₹123.00 per share | ₹54.00 per share |
| Issue Price (Final) | ₹123.00 per share | ₹54.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | 2000 shares |
| Fresh Issue Size | 21,28,000 shares | 1,03,12,000 shares |
| Fresh Issue Size (Amount) | up to ₹26.17 Cr | up to ₹55.68 Cr |
| OFS Issue Size | 0 shares | 27,50,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹14.85 Cr |
| Issue Size Total | 21,28,000 shares | 1,30,62,000 shares |
| Issue Size Total (Amount) | up to ₹26.17 Cr | up to ₹70.53 Cr |
Asston Pharmaceuticals IPO opens on Jul 09, 2025, while Studio LSD IPO opens on Aug 18, 2025. The closing date of Asston Pharmaceuticals IPO and Studio LSD IPO is Jul 11, 2025, and Aug 20, 2025, respectively.
| Asston Pharmaceuticals IPO | Studio LSD IPO | |
|---|---|---|
| Anchor Bid Date | Jul 08, 2025 | |
| Issue Open | Jul 09, 2025 | Aug 18, 2025 |
| Issue Close | Jul 11, 2025 | Aug 20, 2025 |
| Basis Of Allotment (Tentative) | Jul 14, 2025 | Aug 21, 2025 |
| Initiation of Refunds (Tentative) | Jul 15, 2025 | Aug 22, 2025 |
| Credit of Share (Tentative) | Jul 15, 2025 | Aug 22, 2025 |
| Listing date (Tentative) | Jul 16, 2025 | Aug 25, 2025 |
| Anchor Lockin End date 1 | Aug 13, 2025 | |
| Anchor Lockin End date 2 | Oct 12, 2025 |
Asston Pharmaceuticals IPO P/E ratio is 17.83, as compared to Studio LSD IPO P/E ratio of 18.92.
| Asston Pharmaceuticals IPO | Studio LSD IPO | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Asston Pharmaceuticals Limited Financial Information (Restated)Asston Pharmaceuticals Limited's revenue increased by 62% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024.
| EBITDA | |||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 68.76 | 100.00 | |||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 50.66 | 73.50 | |||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 17.83 | 18.92 | |||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹104.70 Cr. | ₹280.22 Cr. | |||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.56% | 53.78% | |||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 51.25% | 57.29% | |||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.68 | ||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.90 | ₹2.85 | |||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 40.36% | 53.78% | |||||||||||||||||||||||||||||||||||||||||||||
In the Asston Pharmaceuticals IPO Retail Individual Investors (RII) are offered 7,46,000 shares while in Studio LSD IPO retail investors are offered 7,46,000 shares. Qualified Institutional Buyers (QIB) are offered 4,25,000 shares in Asston Pharmaceuticals IPO and 1,32,000 shares in Studio LSD IPO.
| Asston Pharmaceuticals IPO | Studio LSD IPO | |
|---|---|---|
| Anchor Investor Reserveration | 6,35,000 shares | |
| Market Maker Reserveration | 1,13,000 shares | 6,88,000 shares |
| QIB | 4,25,000 shares | 1,32,000 shares |
| NII | 3,22,000 shares | 51,72,000 shares |
| RII | 7,46,000 shares | 77,58,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 21,28,000 shares | 1,30,62,000 shares |
Asston Pharmaceuticals IPO subscribed 186.55x in total, whereas Studio LSD IPO subscribed 3.23x.
| Asston Pharmaceuticals IPO | Studio LSD IPO | |
|---|---|---|
| QIB (times) | 85.76x | 1.00x |
| NII (times) | 353.14x | 1.25x |
| Big NII (times) | 424.47x | 0.96x |
| Small NII (times) | 210.85x | 1.84x |
| RII (times) | 172.06x | 4.58x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 186.55x | 3.23x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
